Response to comment on 'Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study'.
作者信息
Jin Liping, Le Jiayuan, Sun Yuming, Zeng Furong
机构信息
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China.
出版信息
Hum Vaccin Immunother. 2024 Dec 31;20(1):2380568. doi: 10.1080/21645515.2024.2380568. Epub 2024 Sep 5.
Abstract
摘要
相似文献
1
Response to comment on 'Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study'.对《COVID-19 全程接种 ZF2001 住院患者的临床特征及危险因素：一项回顾性队列研究》评论的回应
Hum Vaccin Immunother. 2024 Dec 31;20(1):2380568. doi: 10.1080/21645515.2024.2380568. Epub 2024 Sep 5.
2
Letter to the editor to 'Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study'.致编辑的信：“新冠病毒病（COVID-19）完全接种ZF2001疫苗住院患者的临床特征及危险因素：一项回顾性队列研究”
Hum Vaccin Immunother. 2024 Dec 31;20(1):2380566. doi: 10.1080/21645515.2024.2380566. Epub 2024 Aug 20.
3
Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study.COVID-19 住院患者接种 ZF2001 后的临床特征和危险因素：一项回顾性队列研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2355683. doi: 10.1080/21645515.2024.2355683. Epub 2024 Jun 11.
4
Repeated-dose toxicity and immunogenicity evaluation of a recombinant subunit COVID-19 vaccine (ZF2001) in rats.重组亚单位新冠病毒疫苗（ZF2001）在大鼠中的重复给药毒性和免疫原性评价
Front Cell Infect Microbiol. 2025 Apr 22;15:1548787. doi: 10.3389/fcimb.2025.1548787. eCollection 2025.
5
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
6
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.一种基于鼻腔内的 OMV 疫苗可诱导针对 SARS-CoV-2 感染的高黏膜和全身保护免疫。
Front Immunol. 2021 Dec 17;12:781280. doi: 10.3389/fimmu.2021.781280. eCollection 2021.
7
Why Oxford's positive COVID vaccine results are puzzling scientists.为何牛津大学新冠疫苗的阳性结果令科学家们感到困惑。
Nature. 2020 Dec;588(7836):16-18. doi: 10.1038/d41586-020-03326-w.
8
Could mixing COVID vaccines boost immune response?混合接种新冠疫苗能增强免疫反应吗？
Nature. 2021 Feb;590(7846):375-376. doi: 10.1038/d41586-021-00315-5.
9
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.奥密克戎变异株对疫苗加强后免疫血清的中和敏感性低于其他 SARS-CoV-2 变异株。
Emerg Microbes Infect. 2022 Dec;11(1):337-343. doi: 10.1080/22221751.2021.2022440.
10
COVID-19 vaccination and treatment in vulnerable populations.弱势群体中的新冠病毒疫苗接种与治疗
Immunology. 2022 Feb;165(2):141-142. doi: 10.1111/imm.13445.
本文引用的文献
1
Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study.COVID-19 住院患者接种 ZF2001 后的临床特征和危险因素：一项回顾性队列研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2355683. doi: 10.1080/21645515.2024.2355683. Epub 2024 Jun 11.
2
N-antigenemia detection by a rapid lateral flow test predicts 90-day mortality in COVID-19: A prospective cohort study.快速侧向流试验检测 N 抗原血症可预测 COVID-19 患者 90 天死亡率：一项前瞻性队列研究。
Clin Microbiol Infect. 2022 Oct;28(10):1391.e1-1391.e5. doi: 10.1016/j.cmi.2022.05.023. Epub 2022 May 30.
3
Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.西班牙老年 COVID-19 患者队列中托珠单抗和皮质类固醇的预后因素及联合应用。
J Med Virol. 2022 Apr;94(4):1540-1549. doi: 10.1002/jmv.27488. Epub 2021 Dec 7.
4
Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes.建立多变量预测模型的最小样本量：第二部分 - 二分类和生存数据。
Stat Med. 2019 Mar 30;38(7):1276-1296. doi: 10.1002/sim.7992. Epub 2018 Oct 24.
Zotero 插件